NEW YORK (Reuters) - Surgeons conducting clinical trials to test a Medtronic Inc bone-growth protein used in spine surgery, some of whom got at least $62 million from the company, failed to report serious complications in their research papers, the Wall Street Journal reported.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/G9qI6NpUmVg/us-medtronic-idUSTRE75R7XC20110628
Womens Issues Health and Fitness Acne Acupuncture Aerobics Cardio Allergies
No comments:
Post a Comment